ReviewInsulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation
Introduction
With the ageing of the population in the developed world and increasing life expectancy, the looming epidemic of age-related metabolic and neurodegenerative diseases is becoming a growing problem around the globe. Both Alzheimer's disease (AD) and diabetes mellitus, two chronic and age-related diseases, have attained epidemic proportions. AD is the most common form of dementia, affecting approximately 35 million people worldwide (Querfurth and LaFerla, 2010). The prevalence of AD increases exponentially with age, rising from 3% in people aged 65–74 to almost 50% in people aged 85 or older (Pahnke et al., 2009). Additionally, it has been predicted that in 2050 more than 140 million people worldwide will suffer from AD (Pahnke et al., 2009). Similarly, diabetes mellitus is one of the most prevalent metabolic disorders, with the total number of affected people projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al., 2004).
AD is characterized clinically by progressive memory loss and a gradual decline in cognitive function culminating in the premature death of the individual typically 3–9 years after diagnosis (Querfurth and LaFerla, 2010). The pathological features of the disease are the presence of intraneuronal neurofibrillary tangles (NFTs) mainly composed of hyperphosphorylated tau protein and the massive deposition of aggregated amyloid β (Aβ) peptide in the extracellular space as senile plaques (Castellani et al., 2010, Goedert and Spillantini, 2006, Moreira et al., 2009). AD is also characterized by severe neuronal atrophy, which initially appears in the entorhinal region and the temporal lobe, before progressing to the limbic system and subsequently to major areas of the neocortex (Braak and Braak, 1995). There are two forms of AD: the rare familial form (fAD), which is entirely genetic and the more common form that is sporadic (sAD) in origin. The minority of AD cases is of early onset and occurs due to the inheritance of autosomal dominant mutations in three genes: amyloid β precursor protein (APP), presenilin-1 (PS1), and presenilin-2 (PS2) (Rocchi et al., 2003). The great majority of AD cases occur sporadically at a late stage in life, with aging, type 2 diabetes (T2D) and apolipoprotein E4 (APOE4) as the main non-genetic and genetic risk factors (Corder et al., 1993, Hoyer, 2004, Irie et al., 2008, Kivipelto et al., 2002, Luchsinger et al., 2007, Ott et al., 1999).
Diabetes mellitus is a complex metabolic disorder mainly characterized by chronic hyperglycemia and associated with long-term damage, dysfunction, and failure of various organs, including the brain, heart, eyes and kidneys. Two major forms of diabetes mellitus are known: type 1 (T1D) and T2D, with the latter accounting for about 90% of all cases. Diabetes has been posited as a cause of brain atrophy, white matter abnormalities, cognitive impairment, and as a risk factor for dementia (Akisaki et al., 2006, den Heijer et al., 2003, Manschot et al., 2006, Schmidt et al., 2004, Toth et al., 2007). T1D results from the autoimmune destruction of pancreatic β-cells leading to the absolute deficiency of insulin production. Impaired cognitive performance (i.e. decline in learning, memory, problem solving, and mental flexibility) has been observed in T1D subjects (Biessels et al., 2008, Brands et al., 2005) suggesting a detrimental effect of cerebral hyperglycemia, and/or hypoinsulinemia. Along with these deficits, postmortem studies revealed pronounced degeneration of cerebral cortex and neuronal loss in T1D patients compared to age-matched nondiabetic patients (DeJong, 1977, Reske-Nielsen and Lundbaek, 1963). T2D, characterized by a reduction in the ability of insulin to stimulate glucose utilization (insulin resistance) and inadequate pancreatic β-cell insulin secretion in response to hyperglycemia, is related with a greater rate of cognitive deficits (i.e. decreased executive functions, memory skills and, processing speed) in comparison with the general population (Allen et al., 2004, Roriz-Filho et al., 2009). Studies of cerebral structure demonstrated a pronounced cortical, subcortical, and hippocampal atrophy in T2D patients (Roriz-Filho et al., 2009).
Since the first Rotterdam study suggesting an increased risk to develop dementia and AD in patients with T2D, numerous clinical and epidemiological studies were undertaken to further strengthen the interplay between T2D and AD (Kroner, 2009, Ott et al., 1999). Individuals with T2D have nearly a twofold higher risk of AD, independent of the risk for vascular dementia, than nondiabetic individuals (Kroner, 2009). Notably, a study of the Mayo Clinic Alzheimer Disease Patient Registry reported that greater than 80% of AD patients exhibit T2D or abnormal blood glucose levels (Janson et al., 2004), which suggests that these diseases may share a common pathogenetic mechanism responsible for the loss of brain cells and β-cells. Prospective and cross-sectional analyses proposed that diabetes may accelerate the onset of AD, rather than increasing the long-term risk (Pasquier et al., 2006). Furthermore, the risk of AD associated with the APOE ε4 allele has been suggested to be exacerbated by diabetes, as patients with diabetes who are ε4 carriers are twofold more prone to develop AD than nondiabetic individuals who harbor the ε4 allele (Peila et al., 2002). More recently, it was demonstrated that the ApoE ε4 allele modulates APP trafficking and processing, and inhibits Aβ clearance, which indicate that the presence of this allele increases the risk of developing AD (Sjogren et al., 2006).
Meanwhile, some studies failed to demonstrate a correlation between T2D and AD (Bucht et al., 1983, Heitner and Dickson, 1997, Nielson et al., 1996, Wolf-Klein et al., 1988). A postmortem study using brains of diabetic patients found no evidence of increased AD pathology compared to age-matched controls (Heitner and Dickson, 1997). The discrepancies between studies may be due to the current diagnostic practices. The diagnosis of diabetes in most large-scale studies relies on self-report or treatment records. However, this method may underestimate the prevalence of diabetes and exclude its prodromal state of impaired glucose tolerance, which is characterized by hyperinsulinemia and insulin resistance. Furthermore, diabetes is not optimally treated in all patients so that the weak interaction may reflect that well-controlled diabetic patients have less cerebrovascular disease and less impact on AD pathology, while poorly controlled diabetes may have a large impact on AD pathology.
Recently, much effort has been devoted to demystifying the cellular and molecular mechanisms linking diabetes and AD. The present review critically discusses the involvement of amyloidogenesis, dysfunctional insulin signaling along with abnormalities in brain glucose metabolism as critical players in the pathology of both diseases. The role of mitochondrial dysfunction and oxidative stress in the interconnection between diabetes mellitus and AD etiopathogenesis will be debated as well. Elucidation of the putative mechanisms underlying AD and diabetes interrelation could be important to establish new and feasible therapeutic interventions.
Section snippets
Amyloidogenesis in Alzheimer's disease and diabetes
Amyloidogenesis, a condition in which a soluble protein turns to insoluble fibrillar protein aggregates (Chiti and Dobson, 2006), has been considered to be a valid and reliable pathological signature of both AD and T2D. As aforementioned, one of the most prominent neuropathological features of AD is the accumulation of extracellular senile plaques in the brain as a consequence of an abnormal protein processing. The primary components of these plaques are 40- and 42-residue peptides, denoted as
Dysfunctional insulin signaling in Alzheimer's disease and diabetes
Insulin is best known for its involvement in the regulation of glucose metabolism in peripheral tissues. However, this hormone also affects numerous brain functions including cognition, memory and synaptic plasticity through complex insulin/insulin receptor (IR) signaling pathways (Zhao and Alkon, 2001).
Insulin function and signaling disturbances have been proposed as common mechanistic links between diabetes and AD. Indeed, insulin deficiency contributes to the cognitive deficits found in T1D
Abnormal glucose metabolism in Alzheimer's disease and diabetes
Brain glucose metabolism and utilization are vital for normal neuronal function. Neurons are unable to synthesize or store glucose and are dependent on glucose transport across the BBB, a process mediated by glucose transporters (GLUTs) (Scheepers et al., 2004). GLUT-1 and -3 are the predominant GLUT isoforms found in the brain, with GLUT-1 located in neurons, cerebrovascular endothelial cells, astrocytes, and oligodendrocytes, while GLUT-3 is specifically expressed in neurons (Vannucci et al.,
Mitochondrial dysfunction and oxidative stress in Alzheimer's disease and diabetes
Mitochondria are ubiquitous and dynamic organelles that house many crucial cellular processes in eukaryotic organisms. These dynamic organelles are the master coordinators of energy metabolism and are responsible for the generation of over 90% of cellular ATP through the TCA cycle and oxidative phosphorylation (Beal, 2005, Mattson et al., 2008). Notably, mitochondria are one of the major sources of reactive oxygen species (ROS) and, consequently, highly susceptible to oxidative damage. Neurons
Final remarks
Diabetes has been associated with neuronal dysfunction and cognitive decline, increasing the risk of developing AD. The present article provides an updated overview concerning the common pathological features of AD and diabetes and discusses how diabetes exacerbates AD pathology. Amyloidogenesis, impaired brain insulin signaling, abnormal brain glucose metabolism, mitochondrial dysfunction, and oxidative stress are common denominators in AD and diabetes that underlie and potentiate brain
Acknowledgments
This work is supported by the Fundação para a Ciência e a Tecnologia and Fundo Europeu de Desenvolvimento Regional (PTDC/SAU-NEU/103325/2008 and PTDC/SAU-NMC/110990/2009). Sónia C. Correia has a PhD fellowship from the Fundação para a Ciência e a Tecnologia (SFRH/BD/40702/2007).
References (199)
- et al.
The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations
Eur. J. Pharmacol.
(2004) - et al.
Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species
FEBS Lett.
(1989) - et al.
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Trends Neurosci.
(2008) - et al.
Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment
Brain Res.
(1998) - et al.
Cognition and diabetes: a lifespan perspective
Lancet Neurol.
(2008) - et al.
Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease
Neurobiol. Aging
(2002) - et al.
Staging of Alzheimer's disease-related neurofibrillary changes
Neurobiol. Aging
(1995) - et al.
Advanced glycosylation: chemistry, biology, and implications for diabetes and aging
Adv. Pharmacol.
(1992) - et al.
Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia
Biochim. Biophys. Acta
(2010) - et al.
Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine
Free Radic. Biol. Med.
(2001)
Alzheimer disease
Dis. Mon.
Stereospecific interactions are necessary for Alzheimer disease amyloid-beta toxicity
Neurobiol. Aging
Zinc takes the center stage: its paradoxical role in Alzheimer's disease
Brain Res. Brain Res. Rev.
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine
J. Biol. Chem.
Potential roles of insulin and IGF-1 in Alzheimer's disease
Trends Neurosci.
Does insulin dysfunction play a role in Alzheimer's disease?
Trends Pharmacol. Sci.
Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin)
Biochem. Biophys. Res. Commun.
N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease
Free Radic. Biol. Med.
Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation
J. Biol. Chem.
Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons
J. Biol. Chem.
Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice
Brain Res.
Transglutaminase activity is increased in Alzheimer's disease brain
Brain Res.
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice
Exp. Neurol.
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases
J. Biol. Chem.
4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes
Neuroscience
Analysis of microtubule-associated protein tau glycation in paired helical filaments
J. Biol. Chem.
Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1
Neurobiol. Dis.
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death
Neuron
Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons
Neuroscience
Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT)
Diabetes Metab. Res. Rev.
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells
J. Cell Biol.
Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients
Diabetologia
Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes
Biochemistry
Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes
Arch. Neurol.
Mitochondria take center stage in aging and neurodegeneration
Ann. Neurol.
The effects of type 1 diabetes on cognitive performance: a meta-analysis
Diabetes Care
4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats
J. Neuropathol. Exp. Neurol.
Mitochondrial abnormalities in Alzheimer brain: mechanistic implications
Ann. Neurol.
Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type
Acta Med. Scand.
Insulin is a two-edged knife on the brain
J. Alzheimers Dis.
Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters
Synapse
Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease
FASEB J.
Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in neurodegenerative diseases
Hum. Mol. Genet.
Tau is hyperphosphorylated in the insulin-like growth factor-I null brain
Endocrinology
Protein misfolding, functional amyloid, and human disease
Annu. Rev. Biochem.
Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?
Diabetologia
Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes
Diabetes Res.
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function
Nat. Neurosci.
Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease
Endocr. Rev.
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Science
Cited by (156)
Neurology
2023, Ketogenic: The Science of Therapeutic Carbohydrate Restriction in Human HealthAltered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress
2022, Free Radical Biology and MedicineCitation Excerpt :The imbalance between ROS formation and scavenging leads to oxidative damage of intracellular lipids, proteins, and DNA. Subsequently, reduced glucose metabolism in synaptic regions and reduced production of ATP in mitochondria impairs cytochrome oxidase (COX) activities [36]. Neuronal glucose utilization decline with age making old age the most common factor behind AD onset [37].
Ultra-stable dextran conjugated prodrug micelles for oxidative stress and glycometabolic abnormality combination treatment of Alzheimer's disease
2022, International Journal of Biological MacromoleculesmTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder
2021, Free Radical Biology and Medicine